BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 33271935)

  • 1. Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile.
    Zheng M; Mullikin H; Hester A; Czogalla B; Heidegger H; Vilsmaier T; Vattai A; Chelariu-Raicu A; Jeschke U; Trillsch F; Mahner S; Kaltofen T
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
    Shilpi A; Kandpal M; Ji Y; Seagle BL; Shahabi S; Davuluri RV
    JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
    BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and validation of a prognostic index based on a metabolic-genomic landscape analysis of ovarian cancer.
    Zhang QF; Li YK; Chen CY; Zhang XD; Cao L; Quan FF; Zeng X; Wang J; Liu J
    Biosci Rep; 2020 Sep; 40(9):. PubMed ID: 32880385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Role of Zinc Finger Homeobox 4 in Ovarian Serous Cystadenocarcinoma.
    Ha M; Kim J; Park SM; Hong CM; Han ME; Song P; Kang CD; Lee D; Kim YH; Hur J; Oh SO
    Genet Test Mol Biomarkers; 2020 Mar; 24(3):145-149. PubMed ID: 32105524
    [No Abstract]   [Full Text] [Related]  

  • 6. The impact on high-grade serous ovarian cancer of obesity and lipid metabolism-related gene expression patterns: the underestimated driving force affecting prognosis.
    Cuello MA; Kato S; Liberona F
    J Cell Mol Med; 2018 Mar; 22(3):1805-1815. PubMed ID: 29266765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
    Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
    Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel defined programmed cell death related gene signature for predicting the prognosis of serous ovarian cancer.
    Zhan F; Guo Y; He L
    J Ovarian Res; 2024 Apr; 17(1):92. PubMed ID: 38685095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and Validation of an Immune-Related Prognostic Signature for Ovarian Cancer Based on Weighted Gene Coexpression Network Analysis.
    An Y; Yang Q
    Biomed Res Int; 2020; 2020():7594098. PubMed ID: 33381581
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Xu Z; Zhuang L; Wang X; Li Q; Sang Y; Xu J
    Future Oncol; 2020 Sep; 16(25):1921-1930. PubMed ID: 32915667
    [No Abstract]   [Full Text] [Related]  

  • 11. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
    Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
    DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.
    Choi YL; Kim J; Kwon MJ; Choi JS; Kim TJ; Bae DS; Koh SS; In YH; Park YW; Kim SH; Ahn G; Shin YK
    Histol Histopathol; 2007 Nov; 22(11):1185-95. PubMed ID: 17647191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Hub Genes in High-Grade Serous Ovarian Cancer Using Weighted Gene Co-Expression Network Analysis.
    Wu M; Sun Y; Wu J; Liu G
    Med Sci Monit; 2020 Mar; 26():e922107. PubMed ID: 32180586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pericytes Promote Malignant Ovarian Cancer Progression in Mice and Predict Poor Prognosis in Serous Ovarian Cancer Patients.
    Sinha D; Chong L; George J; Schlüter H; Mönchgesang S; Mills S; Li J; Parish C; Bowtell D; Kaur P;
    Clin Cancer Res; 2016 Apr; 22(7):1813-24. PubMed ID: 26589433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis.
    Espinosa I; Catasus L; Canet B; D'Angelo E; Muñoz J; Prat J
    Mod Pathol; 2011 Jun; 24(6):846-54. PubMed ID: 21317880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased Expression of LYNX1 in Ovarian Serous Cystadenocarcinoma Predicts Poor Prognosis.
    Liu H; Wang A; Ma Y
    Biomed Res Int; 2020; 2020():1392674. PubMed ID: 33299855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
    Peng Y; Wang H; Huang Q; Wu J; Zhang M
    J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
    Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
    Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
    Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q
    Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis.
    Li Y; Li L
    J Ovarian Res; 2019 Nov; 12(1):106. PubMed ID: 31703725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.